Brian M. Culley - Sep 30, 2021 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role: President and CEO, Director
Signature: /s/ Brian M. Culley
Stock symbol: LCTX
Transactions as of: Sep 30, 2021
Transactions value $: -$13,464
Form type: 4
Date filed: 10/12/2021, 04:27 PM
Previous filing: Jun 30, 2021
Next filing: Jan 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LCTX	Common Shares, no par value	Options Exercise		+15.5K	+27.68%		71.3K	Sep 30, 2021	Direct	F1, F2
transaction	LCTX	Common Shares, no par value	Tax liability	-$13.5K	-5.34K	-7.5%	$2.52	65.9K	Sep 30, 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LCTX	Restricted Stock Units	Options Exercise	$0	-15.5K	-25%	$0.00	46.4K	Sep 30, 2021	Common Shares	15.5K	$0.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis.
F2	Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing.
F3	Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
F4	The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.